VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Figlin on Advice for Oncologists Treating RCC

Robert Figlin, MD
Published: Tuesday, Dec 22, 2015



Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, provides advice to community oncologists who are treating patients with renal cell carcinoma (RCC).

Figlin explains that, for practitioners, the RCC field can be complicated. First, oncologists need to navigate through the various therapeutic options and choose which therapy is best for individual patients. Additional challenges include proper management of toxicities associated with some of the newer therapies and treatment of patients with comorbidities.

It is also important to understand optimal dosing and scheduling of treatment, he adds. Practitioners should also have a treatment plan for patients, so that there is an understanding of which therapies should be administered in various settings.
 


Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, provides advice to community oncologists who are treating patients with renal cell carcinoma (RCC).

Figlin explains that, for practitioners, the RCC field can be complicated. First, oncologists need to navigate through the various therapeutic options and choose which therapy is best for individual patients. Additional challenges include proper management of toxicities associated with some of the newer therapies and treatment of patients with comorbidities.

It is also important to understand optimal dosing and scheduling of treatment, he adds. Practitioners should also have a treatment plan for patients, so that there is an understanding of which therapies should be administered in various settings.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x